Coyne Healthcare - Bio-Curcumin

Notable Published Studies Completed on BCM-95 and
AKBAMAX as of January 2018
A randomized, pilot study to assess the efficacy and safety of Curcumin in patients with active rheumatoid
arthritis, Chandran B et al., Phytother Res, 2012;26(11):1719-25.
A pilot clinical trial of radioprotective effects of Curcumin supplementation in patients with prostate cancer,
Hejazi J et al., J Cancer Sci Ther, 2013;5:320-324.
Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the
management of knee osteoarthritis, Kizhakkedath R, Mol Med Rep, 2013;8(5):1542-8.
Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial, Sanmukhani J
et al., Phytother Res, 2014:28(4):579-85.
Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
Lopresti AL et al., J Affect Disord, 2014;167:368-75.
Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor
microenvironment: potential role of EMT, Buhrmann C et al., PLoS ONE 9(9): e107514.
Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density
cultures, Shakibaei M et al., PLoS ONE 9(1): e85397.
Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of
colorectal cancer, Shakibaei M et al., BMC Cancer, 2015;15:250.
Novel evidence for Curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a
and miR-27a in colorectal cancer, Toden S et al., Cancer Prev Res (Phila), 2015;8(5):431-43.
Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the
potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of
change. Lopresti AL et al., Eu Neuropsychopharmacol, 2015;25(1):38-50.
Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of
epithelial-to-mesenchymal transition in chemoresistant colorectal cancer, Toden S et al., Carcinogenesis,
2015;36(3):355-67.
BCM-95 and (2-hydroxypropyl)-ß-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in
Sap C-deficient fibroblasts, Tatti M et al., Hum Mol Genet, 2015;24(15):4198-211.
Evaluation of antidepressant like activity of Curcumin and its combination with Fluoxetine and Imipramine:
an acute and chronic study, Sanmukhani J et al., Acta Pol Pharm, 2011;68(5):769-75.
Comparative study of the efficacy of Curcumin and Turmeric oil as chemopreventive agents in oral
submucous fibrosis: a clinical and histopathological evaluation, J Deepa Das A et al., Indian Acad Oral Med
Radiol, 2010;22(2):88-92.
A pilot cross-over study to evaluate human oral bioavailability of BCM-95 ® CG, a novel bioenhanced
preparation of Curcumin, Antony B et al., Indian J Pharm Sci 2008;70(4):445-449.
Six-month double-blind, placebo-controlled, pilot clinical trial of curcumin in patients with Alzheimer’s
disease, Baum L et al., J Clin Psychopharmacol, 2008:28:110-113.
Curcumin effects on blood lipid profile in a 6-month human study, Baum L et al., Pharmaco Res, 56 (2007)
2007;56(6):509-514.